ORTHOTROPHIX, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2011-05-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.orthotrophix.com
Clinical Trials
4
Active:0
Completed:3
Trial Phases
1 Phases
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (100.0%)53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee
Phase 2
Recruiting
- Conditions
- Osteoarthritis (OA) of the Knee
- Interventions
- Drug: TPX-100 200mg, Once weekly for 4 weeksOther: PBS
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-08-27
- Lead Sponsor
- OrthoTrophix, Inc
- Target Recruit Count
- 270
- Registration Number
- NCT06865079
- Locations
- 🇺🇸
Elite Clinical Network, Scottsdale, Arizona, United States
🇺🇸Noble Clinical Research, Tucson, Arizona, United States
🇺🇸Legent Orthopedic Hospital, Carrolton, California, United States
A Prospective Observational Study to Evaluate Long-term Changes in Cartilage Morphology in Subjects Who Previously Received TPX-100 or Placebo in Study TPX-100-1 for Patellar Osteoarthritis Involving Both Knees
Completed
- Conditions
- Mild to Moderate Knee OA
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- OrthoTrophix, Inc
- Target Recruit Count
- 54
- Registration Number
- NCT03125499
- Locations
- 🇺🇸
Dr. Samy Metyas, Covina, California, United States
A Study Evaluating the Safety and Efficacy of a Second Course of TPX-100 in Subjects Who Previously Received TPX-100 for Patellar Osteoarthritis Involving Both Knees
Phase 2
Completed
- Conditions
- Knee Osteoarthritis
- Interventions
- Drug: TPX-100 200 mg 4 times weekly for 4 weeks
- First Posted Date
- 2016-07-20
- Last Posted Date
- 2017-09-19
- Lead Sponsor
- OrthoTrophix, Inc
- Target Recruit Count
- 14
- Registration Number
- NCT02837900
A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees
Phase 2
Completed
- Conditions
- Knee Osteoarthritis
- Interventions
- Drug: TPX-100 20mgDrug: TPX-100 100mgDrug: TPX-100 200mgDrug: TPX-100 50mgDrug: Placebo
- First Posted Date
- 2013-08-19
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- OrthoTrophix, Inc
- Target Recruit Count
- 120
- Registration Number
- NCT01925261
- Locations
- 🇺🇸
C3 Clinical Research Associates, Seattle, Washington, United States
News
No news found